Isturisa for Cushing’s disease now available in United States
Isturisa is now available for sale and distribution in the United States, according to a press release from the manufacturer.
In March 2020, Isturisa was approved by the U.S. Food and Drug Administration, for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative
“Isturisa is a meaningful addition to the treatment options for Cushing’s disease and helps address the significant unmet need for patients affected by this rare and life-threatening disease,” said Richard J. Auchus MD, PhD, a professor of medicine at the University of Michigan School of Medicine in the release. “Isturisa mechanistically inhibits the final step of the cortisol synthesis pathway. Achieving control of cortisol production is an important strategy to help patients manage Cushing’s disease, and it may be crucial for mitigating the risk for comorbidities associated with hypercortisolism.”
Read the full press release here.